RaQualia Pharma Inc. (TYO:4579)
1,003.00
+3.00 (0.30%)
At close: Feb 6, 2026
RaQualia Pharma Revenue
RaQualia Pharma had revenue of 775.05M JPY in the quarter ending September 30, 2025, a decrease of -19.13%. This brings the company's revenue in the last twelve months to 3.05B, up 9.87% year-over-year. In the year 2024, RaQualia Pharma had annual revenue of 3.11B with 63.44% growth.
Revenue (ttm)
3.05B
Revenue Growth
+9.87%
P/S Ratio
8.56
Revenue / Employee
47.64M
Employees
64
Market Cap
26.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.11B | 1.21B | 63.44% |
| Dec 31, 2023 | 1.90B | -1.02B | -34.85% |
| Dec 31, 2022 | 2.92B | 142.00M | 5.12% |
| Dec 31, 2021 | 2.78B | 1.67B | 150.77% |
| Dec 31, 2020 | 1.11B | -595.00M | -34.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.61B |
| ReproCELL | 2.63B |
| Japan Tissue Engineering | 2.26B |
| Immuno-Biological Laboratories | 1.01B |
| AnGes | 818.00M |
| Healios K.K. | 97.00M |
| Renascience | 87.00M |
| Oncolys BioPharma | 28.55M |